Segment Data (Details)	3 Months Ended
	Mar. 31, 2025 USD ($) Segment	Mar. 31, 2024 USD ($)	Dec. 31, 2024 USD ($)
Segment Information
Number of reportable segments | Segment	2
Right-of-use asset	$ 1,211,000		$ 936,000
External revenue	2,214,000	$ 2,351,000
Cost of revenue	515,000	430,000
Research and development	3,730,000	4,312,000
Sales and marketing	2,493,000	1,443,000
General and administrative	4,897,000	4,381,000
Interest	(56,000)	611,000
Consolidated net comprehensive loss	(10,858,000)	(9,151,000)
Segment net loss	(10,596,000)	(9,368,000)
Segment assets	51,460,000		53,425,000
Napo Therapeutics Lease Office | Europe
Segment Information
Right-of-use asset	185,000		230,000
Property, Plant, and Equipment, Right-of-Use Assets, and Intangible Assets | US
Segment Information
Right-of-use asset	19,500,000		19,600,000
Product revenue, net
Segment Information
External revenue	2,171,000	2,351,000
Operating Segments
Segment Information
External revenue	2,214,000	2,351,000
Cost of revenue	515,000	430,000
Research and development	3,725,000	4,312,000
Sales and marketing	2,493,000	1,443,000
General and administrative	5,342,000	4,381,000
Other segment items	1,487,000	326,000
Segment expenses	13,562,000	10,892,000
Consolidated net comprehensive loss	(11,348,000)	(8,541,000)
Segment assets	222,299,000		218,920,000
Operating Segments | Human Health
Segment Information
External revenue	2,138,000	2,303,000
Cost of revenue	505,000	415,000
Research and development	3,113,000	3,491,000
Sales and marketing	2,396,000	1,372,000
General and administrative	2,004,000	1,823,000
Other segment items	311,000	(415,000)
Segment expenses	8,329,000	6,686,000
Consolidated net comprehensive loss	(6,191,000)	(4,383,000)
Segment assets	44,628,000		44,117,000
Operating Segments | Animal Health
Segment Information
External revenue	76,000	48,000
Cost of revenue	10,000	15,000
Research and development	612,000	821,000
Sales and marketing	97,000	71,000
General and administrative	3,338,000	2,558,000
Other segment items	1,176,000	741,000
Segment expenses	5,233,000	4,206,000
Consolidated net comprehensive loss	(5,157,000)	(4,158,000)
Segment assets	177,671,000		174,803,000
Eliminations And Reconciling Items [Member]
Segment Information
Consolidated net comprehensive loss	490,000	$ (610,000)
Segment Reconciling Items
Segment Information
Segment assets	(29,232,000)		(29,232,000)
Intersegment Eliminations
Segment Information
Segment assets	$ (141,607,000)		$ (136,263,000)